Pfizer (PFE -0.7%) says Phase 3 studies of its tofacitinib monotherapy program for rheumatoid...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE -0.7%) says Phase 3 studies of its tofacitinib monotherapy program for rheumatoid arthritis show it superior to methotrexate in inhibiting structural damage and reducing signs and symptoms in methotrexate-naïve patients. If approved, tofacitinib would be the first treatment in a new class of medicines - known as JAK inhibitors - and the first new oral disease-modifying anti-rheumatic drug in more than 10 years.